Clarivate Reports $268.6 Million Quarterly Loss Amid Restructuring

Total revenues for the quarter reached $587.3 million, down from $621.4 million in the same period last year, a decline the company attributed to divestitures and the ongoing wind-down of specific product groups. Organic subscription growth of 0.7% was unable to offset a 15.7% drop in organic transactional revenues, as clients increasingly shifted toward subscription-based models. CEO Matti Shem Tov emphasized that the company’s ongoing Value Creation Plan remains the primary driver of its long-term strategy, aimed at achieving organic growth acceleration and simplifying the company’s portfolio through the pending sale of its Life Sciences & Healthcare segment.

Financial discipline remains a central theme for the management team. CFO Jonathan Collins noted that Clarivate reduced its total debt by more than $200 million during the first half of the year, utilizing strong cash flow and opportunistic repurchases to strengthen the balance sheet. While the company posted a net loss of $308.8 million for the first six months of 2026, adjusted EBITDA for the same period stood at $488.4 million. Looking ahead, Clarivate maintains its full-year guidance, projecting adjusted EBITDA between $980 million and $1.04 billion, with anticipated free cash flow reaching up to $435 million.